BG Medicine, Inc. Common Stock

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch BGMD and buy or sell other stocks, ETFs, and their options commission-free!

About BGMD

BG Medicine, Inc. is a life sciences company, which engages in the provision of developing and delivering innovative solutions for healthcare providers that provide insight and transform the clinical care of heart failure and related disorders. The firm distributes products such as BGM Galectin-3 to clinical laboratories, hospitals, and healthcare providers. 

CEO
Paul R. Sohmer, MD
CEOPaul R. Sohmer, MD
Employees
5
Employees5
Headquarters
Waltham, Massachusetts
HeadquartersWaltham, Massachusetts
Founded
2000
Founded2000
Employees
5
Employees5

BGMD Key Statistics

Market cap
1.14K
Market cap1.14K
Price-Earnings ratio
Price-Earnings ratio
Dividend yield
Dividend yield
Average volume
66.10
Average volume66.10
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$0.0001
52 Week high$0.0001
52 Week low
$0.00
52 Week low$0.00

Stock Snapshot

With a market cap of 1.14K, BG Medicine, Inc. Common Stock(BGMD) trades at $0.00.

On 2026-07-25, BG Medicine, Inc. Common Stock(BGMD) stock opened at —, reached a high of —, and a low of —.

BG Medicine, Inc. Common Stock(BGMD) shares are trading with a volume of 0, against a daily average of 66.1.

In the last year, BG Medicine, Inc. Common Stock(BGMD) shares hit a 52-week high of $0.00 and a 52-week low of $0.00.

In the last year, BG Medicine, Inc. Common Stock(BGMD) shares hit a 52-week high of $0.00 and a 52-week low of $0.00.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.